Nightstar Therapeutics PLC (NASDAQ:NITE) – Investment analysts at Wedbush reduced their Q3 2018 earnings estimates for shares of Nightstar Therapeutics in a note issued to investors on Tuesday, September 25th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.43) per share for the quarter, down from their prior forecast of ($0.42). Wedbush currently has a “Outperform” rating and a $31.00 price target on the stock. Wedbush also issued estimates for Nightstar Therapeutics’ FY2018 earnings at ($1.61) EPS, FY2019 earnings at ($1.64) EPS, FY2020 earnings at ($1.57) EPS, FY2021 earnings at ($1.58) EPS and FY2022 earnings at $0.11 EPS.
Several other brokerages have also recently commented on NITE. Zacks Investment Research cut shares of Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, June 6th. Chardan Capital restated a “buy” rating and set a $40.00 price objective on shares of Nightstar Therapeutics in a research note on Wednesday, June 6th. Janney Montgomery Scott started coverage on shares of Nightstar Therapeutics in a research note on Wednesday, August 22nd. They set a “buy” rating and a $34.00 price objective for the company. BMO Capital Markets set a $41.00 price objective on shares of Nightstar Therapeutics and gave the company a “buy” rating in a research note on Monday. Finally, Leerink Swann lifted their price objective on shares of Nightstar Therapeutics from $30.00 to $35.00 and gave the company a “positive” rating in a research note on Monday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Nightstar Therapeutics currently has a consensus rating of “Buy” and an average target price of $32.86.
Shares of NASDAQ NITE opened at $19.00 on Thursday. Nightstar Therapeutics has a 12 month low of $10.01 and a 12 month high of $29.55.
Nightstar Therapeutics (NASDAQ:NITE) last announced its quarterly earnings data on Monday, August 13th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.12.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Woodford Investment Management Ltd purchased a new position in shares of Nightstar Therapeutics during the 2nd quarter valued at approximately $5,024,000. Millennium Management LLC purchased a new position in shares of Nightstar Therapeutics during the 1st quarter valued at approximately $507,000. Redmile Group LLC increased its holdings in shares of Nightstar Therapeutics by 0.9% during the 2nd quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock valued at $28,567,000 after purchasing an additional 16,500 shares in the last quarter. Stanley Laman Group Ltd. purchased a new position in shares of Nightstar Therapeutics during the 2nd quarter valued at approximately $195,000. Finally, Bank of America Corp DE purchased a new position in shares of Nightstar Therapeutics during the 2nd quarter valued at approximately $132,000. Institutional investors and hedge funds own 28.62% of the company’s stock.
About Nightstar Therapeutics
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy.
Featured Story: Tariff
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.